menu
    • menu
    [{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HaemaLogiX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaemaLogiX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HaemaLogiX \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"Cartherics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTH-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cartherics \/ Undisclosed"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Vivesto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Divestment","leadProduct":"Cantrixil","moa":"SMETI","graph1":"Oncology","graph2":"Preclinical","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kazia Therapeutics \/ Vivesto","highestDevelopmentStatusID":"4","companyTruncated":"Kazia Therapeutics \/ Vivesto"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kazia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Kazia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Vivesto

                            Deal Size : $1.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Kazia Sells IP And Trademarks Rights For Cantrixil Asset

                            Details : Vivesto is currently exploring TRX-E-002-1 (cantrixil), a potent and selective third generation benzopyran SMETI inhibitor, preclinically for the treatment of hematological cancers.

                            Product Name : TRXE-002-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 31, 2025

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Vivesto

                            Deal Size : $1.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kazia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Kazia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paxalisib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : QIMR Berghofer Medical Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kazia Executes Licensing Agreement with Qimr Berghofer

                            Details : Kazia receives an exclusive, worldwide, licence for the development of any drugs, including GDC-0084 (paxalisib) within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.

                            Product Name : GDC-0084

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Paxalisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : QIMR Berghofer Medical Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cartherics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Cartherics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTH-401

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cartherics Raises $15M To Advance Cell Therapy Programs

                            Details : The funding will support the clinical trial for CTH-401, the Company’s lead cell therapy and the only natural killer (NK) cell product currently under development for ovarian cancer.

                            Product Name : CTH-401

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : CTH-401

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Hosts Corporate Update Call on Recent Progress and Positive Results

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Product Name : PRP

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 22, 2024

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Aust...

                            Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                            Product Name : PRP

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 15, 2023

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            FivepHusion

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            FivepHusion

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil,Calcium Folinate,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Allarity Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ ...

                            Details : Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DR...

                            Product Name : Deflexifol

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Fluorouracil,Calcium Folinate,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Allarity Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Propanc Biopharma

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Peter MacCallum Cancer Centre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Propanc Biopharma Announces Strategic Pharma Partnering Initiative

                            Details : The partnership aims for Propanc's lead product candidate, PRP (pancreatic proenzyme), a mixture of two proenzymes, trypsinogen and chymotrypsinogen, advancing towards a Phase I, first-in-human study in advanced cancer patients.

                            Product Name : PRP

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Chymotrypsinogen,Trypsinogen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Peter MacCallum Cancer Centre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amplia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Amplia Therapeutics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer

                            Details : AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.

                            Product Name : AMP945

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 29, 2023

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HaemaLogiX

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            HaemaLogiX

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HaemaLogiX To Present Final Data from Anti-KMA CAR-T Preclinical Studies At AACR

                            Details : Anti-KMA CAR-T is a myeloma-specific antigen not found on normal cells. It has completed preclinical studies and is being developed to treat kappa-type multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Radiopharm Theranostics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. 177-Lu

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical ...

                            Details : The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.

                            Product Name : RAD206

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 19, 2022

                            Lead Product(s) : n.c.a. 177-Lu

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth